文献速递创面修复瘢痕与激光

EHTIC研究:基于组织因子的新型止血剂在皮肤移植中的评估

EHTIC study: Evaluation of a new hemostatic agent based on tissue factor in skin grafting procedures.
PubMed 文献 · Burns · 2017-01-23

EHTIC研究为II期随机双盲安慰剂对照试验,评估基于重组人组织因子的新型局部止血剂TT-173在皮肤移植供区止血的有效性和安全性。

要点

  • TT-173显著缩短供区出血时间,从7分钟降至3分钟(p<0.0001)。
  • TT-173组所有患者出血在10分钟评估期内停止。
  • 未观察到产品相关不良事件、全身吸收或免疫原性反应。

核心结论

  • 新型止血剂TT-173在皮肤移植供区止血中有效且安全,可显著减少出血。

研究设计与样本

  • II期随机、平行、双盲、安慰剂对照试验,TT-173组38例,安慰剂组33例。

主要发现

  • TT-173治疗将出血时间从7分钟显著缩短至3分钟(Log-Rank p<0.0001)。
  • TT-173组所有患者出血在10分钟评估期内停止。
  • 安慰剂组24.24%患者需要额外措施止血(Fisher p=0.0013)。
  • 未观察到产品相关不良事件、全身吸收、供区愈合干扰或针对TT-173的免疫反应。

临床怎么用

  • TT-173可作为皮肤移植供区局部止血的潜在选择,减少出血并降低额外止血措施需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excessive bleeding is a major concern in scar debridement and grafting procedures. TT-173 is a new topical hemostatic agent based on recombinant human tissue factor that has shown promising results in patients who underwent tooth extraction. EHTIC study sought to evaluate the efficacy and safety of TT-173 to reduce the bleeding in donor sites of skin grafting procedures. METHODS: EHTIC study was a phase II, randomized, parallel, double blind, placebo controlled trial. Patients received TT-173 (n=38) or placebo (n=33) sprayed over donor site after graft harvest. Time to hemostasis and incidence of adverse events were recorded. Systemic absorption of the product and its immunogenicity were also measured during the follow up of the subjects. RESULTS: Treatment with TT-173 significantly reduced the bleeding time from 7 to 3min (Log-Rank p<0.0001). Moreover, bleeding stopped within the 10min of evaluation period in all the patients that received TT-173. In contrast, 24.24% of patients from placebo group required additional measures to arrest hemorrhage (Fisher p=0.0013). Product related adverse events, systemic absorption into blood stream, interferences with the healing of the donor site or immunogenic reaction against TT-173 were not observed. CONCLUSION: The new hemostatic agent TT-173 has proven efficacious and safe to reduce the bleeding from donor site. This study paves the way for further investigation of the product as topical hemostatic treatment in plastic surgery and other surgical indications.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Rojas S, Pérez Del Caz MD, Esteban Vico JR, et al. EHTIC study: Evaluation of a new hemostatic agent based on tissue factor in skin grafting procedures. Burns. 2017. PMID: 28126447. doi:10.1016/j.burns.2017.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。